J&J adds 200 jobs at new biopharma facility in Ireland

强生投资3.5亿美元生物制剂工厂宣布开幕,增加工作岗位200个

2019-10-09 10:21:12 FiercePharma

本文共575个字,阅读需2分钟

Johnson & Johnson's Janssen has had biopharma operations in Ringaskiddy, Co. Cork for nearly 15 years. Now it has a new $350 million facility and added 200 jobs.  The official opening, which was announced by IDA Ireland, boosted the site’s size by 19,100 square meters (205,590 square feet).  “Our Ringaskiddy facility is an important part of our global manufacturing network and expanding our capabilities here will allow us to pursue innovative solutions …” Kathy Wengel, J&J’s chief global supply chain officer, said in a statement.  The company started on the €300 million project in 2017. The additions included expansion of an existing warehouse, laboratory and administration buildings, and expansion of the wastewater treatment plant to accommodate increased volumes. RELATED: Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report At the time the company said the new plant would bolster capacity of APIs for drugs that treat “multiple myeloma, rheumatoid arthritis and Crohn’s disease.”  While it didn’t specifically identify the products to be made there, J&J sells blockbuster Remicade for rheumatoid arthritis and Crohn’s disease, as well as Simponi for treating rheumatoid arthritis and Stelara for treating Crohn's disease.  According to a new forecast from GlobalData, Stelara is expected to be the ninth-best selling drug globally in 2025 with $7.5 billion in sales.
强生公司的杨森(Janssen)在 Ringaskiddy , Co . Cork 拥有近15年的生物制药业务。现在,它有一个新的3.5亿美元的设施,增加了200个工作岗位。 由爱尔兰国际开发协会( IDA Ireland )宣布的正式开幕仪式,使该网站的面积增加了19,100平方米(205,590平方英尺)。 “我们的 Ringaskiddy 工厂是我们全球制造网络的重要组成部分,扩大我们在这里的能力将使我们能够寻求创新的解决方案……”强生(J&J)首席全球供应链官 KathyWegel 在一份声明中说。 公司于2017年启动3亿欧元项目。新增的设施包括扩建现有仓库、实验室和行政大楼,以及扩建污水处理厂以容纳更多的水量。 相关报道:默克(Merck)、百时美施贵宝(BMS)、艾伯维(AbbVie)重磅炸弹将在2025年统治药品销售 当时该公司表示,新工厂将提高“多发性骨髓瘤、类风湿关节炎和克罗恩病”药物的原料药产能。虽然它没有具体确定将在那里生产的产品,但强生(J&J)公司销售的重磅炸弹 Remicade 用于类风湿关节炎和克罗恩病,以及 Simponi 用于治疗类风湿关节炎和 Stelara 用于治疗克罗恩病。 根据 GlobalData 的最新预测, Stelara 有望在2025年成为全球第九大畅销药物,销售额达75亿美元。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文